263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 84
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1.2M | 1.26M | 1964 |
Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 56.72k | N/A | 1967 |
Mr. Michael Breininger CPA, M.B.A. | Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller | N/A | N/A | 1982 |
Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | N/A | N/A | 1983 |
John Kouch J.D. | General Counsel | N/A | N/A | N/A |
Ms. Tiffany J. Hamilton M.B.A. | Head of Corporate Communications | N/A | N/A | N/A |
Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | N/A | N/A | N/A |
Ms. Jyothy Pillai M.S. | Head of Regulatory & Quality | N/A | N/A | N/A |
Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | N/A | N/A | N/A |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 10.